NovoBioPharma, Partnership of Top Life Science Experts, Launches

       NovoBioPharma, Partnership of Top Life Science Experts, Launches

PR Newswire

CAMBRIDGE, Mass., June 11, 2013

CAMBRIDGE, Mass., June 11, 2013 /PRNewswire/ --NovoBioPharma, a partnership
of experts collaborating with life science organizations to provide
comprehensive medical, scientific, regulatory, business and financial advisory
services, launched today. The global business is comprised of four principals,
all experts in their fields, who partnered to create an entity to help life
science companies and institutions to cost-efficiently advance drug,
diagnostic and device candidates by leveraging opportunities from conception
through clinical development, and ultimately, regulatory approval.

With decades of experience and a global network in all areas of business,
finance, drug, diagnostic and device development, NovoBioPharma offers
services in capital sourcing and management, business development,
intellectual property, quality control, manufacturing, study design, and
protocol development. Simply put, NovoBioPharma covers every facet of the
risky and costly work of developing life science breakthroughs.

The NovoBioPharma team is:

Bernie Rudnick, MBA, Chief Business Officer, is founder and managing partner
of CapGenic Advisors, LLC, and a founding member of several Angel investing
groups. Mr. Rudnick has substantial experience investing and guiding
investments in entrepreneurial companies; he has led capital formation
totaling more than $530 million in the past ten years and $3B during the last
15 years. Mr. Rudnick, a serial entrepreneur, founded, managed and advised
numerous companies in the life sciences, including diagnostic, therapeutic and
clinical software environments. Mr. Rudnick is experienced in forms of
capital formation including angel networks, venture capital funds, SBIR and
other government grant programs. He is a graduate of Penn State and Northwood

Ira Wallace, MD, MBA is Chief Development Officer for NovoBioPharma. Dr.
Wallace has been involved in pharmaceutical, biotech and medical device
companies as a CEO, founder, board member and consultant. In addition, Dr.
Wallace is experienced in technology transfer and intellectual property
strategies and is a founding member and partner in a number of Angel
investment groups. A graduate of the University of Pennsylvania, Dr. Wallace
earned his medical degree at Drexel Medical School and his MBA at Columbia.

Shahin Gharakhanian MD, Head, Pharmaceutical Medicine, is an infectious
diseases and internal medicine trained physician with over 20 years experience
in the pharmaceutical industry and clinical practice. His last position was
Vice President in the Medicines Development Group/Global R&D at Vertex
Pharmaceuticals, Inc. Cambridge MA, USA. In industry, Dr. Gharakhanian has
driven: strategic leadership, clinical development and medical affairs.
Overall, he has handled projects for twelve different pharmaceutical
companies, ten different brands and four drug launches in Asia, Canada, EU and
the United States. His most recent major New Drug Application/launch
experience was in 2011. Dr. Gharakhanian earned his specialty medical degrees
at University of Paris, and trained/practiced in AP-HP, Paris, France, the
largest hospital system in Europe and one of the largest in the world.

Andrew D. Luber, PharmD Chief Scientific Officer, is an infectious diseases
trained clinical pharmacist/pharmacologist with over 18 years experience
working with the pharmaceutical industry as an investigator, key opinion
leader, speakers bureau, steering committee and advisory board member. In
addition, he has served as a clinical consultant to large and early stage
pharmaceutical companies. Dr. Luber has been an investigator in more than 70
clinical trials including four Phase 1a first in human studies and specializes
in early stage drug development. Dr. Luber received his doctor of pharmacy at
Temple University and did his post-doctoral residencies and research
fellowship at the University of California, San Francisco Medical Center and
School of Pharmacy.

For more information, visit the website at NovoBioPharma
Contact: Andrew D. Luber, PharmD 1-856-258-0850

SOURCE NovoBioPharma

Press spacebar to pause and continue. Press esc to stop.